Statements (79)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:atccode |
L02 AE01
|
| gptkbp:brand |
gptkb:Trelstar
gptkb:Trelstar_Depot |
| gptkbp:clinical_trial |
Phase III
Phase III trials Efficacy studies Safety studies |
| gptkbp:clinical_use |
hormone therapy
hormonal therapy |
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to triptorelin |
| gptkbp:dosage_form |
11.25 mg
|
| gptkbp:duration |
depends on response
typically long-term |
| gptkbp:effective_date |
2004-12-30
approved in the UK |
| gptkbp:excretion |
urine
|
| gptkbp:financial_support |
report any unusual bleeding
monitor for signs of adrenal insufficiency avoid in patients with severe liver impairment caution in patients with diabetes monitor bone density |
| gptkbp:form |
suspension
|
| gptkbp:formulation |
suspension
|
| gptkbp:frequency |
every 3 months
|
| https://www.w3.org/2000/01/rdf-schema#label |
Trelstar
|
| gptkbp:indication |
gptkb:hormone-sensitive_prostate_cancer
advanced prostate cancer |
| gptkbp:ingredients |
gptkb:triptorelin
|
| gptkbp:interacts_with |
anticoagulants
other Gn RH analogs CYP3 A4 inducers CYP3 A4 inhibitors |
| gptkbp:is_monitored_by |
side effects
PSA levels testosterone levels |
| gptkbp:legal_status |
prescription only
|
| gptkbp:lifespan |
3 hours
|
| gptkbp:manufacturer |
gptkb:Ipsen
|
| gptkbp:marketed_as |
gptkb:Europe
gptkb:Asia gptkb:Australia gptkb:Canada gptkb:USA gptkb:Trelstar_LA |
| gptkbp:mechanism_of_action |
Gn RH agonist
|
| gptkbp:packaging |
vial
single-dose vial |
| gptkbp:patient_population |
adult men
|
| gptkbp:pharmacokinetics |
subcutaneous absorption
rapidly absorbed peak plasma concentration in 1-2 hours protein binding 90% Gn RH agonist suppresses testosterone production |
| gptkbp:related_products |
gptkb:goserelin
gptkb:buserelin gptkb:histrelin gptkb:leuprolide |
| gptkbp:rounds |
urine
|
| gptkbp:route_of_administration |
injection
intramuscular injection |
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
fatigue
nausea weight gain injection site reactions hot flashes decreased libido |
| gptkbp:storage |
room temperature
|
| gptkbp:structure |
gptkb:protein
C64 H86 N18 O13 S |
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:used_for |
gptkb:Oncology
|
| gptkbp:bfsParent |
gptkb:Gn_RH_agonists
gptkb:Zoladex |
| gptkbp:bfsLayer |
5
|